https://orcid.org/0000-0001-9507-7454
Figures
Abstract
Objectives
Semi-quantitative CT score is generally used for evaluating the disease status of Mycobacterium abscessus (Mab) Pulmonary disease (Mab-PD). However, its accuracy and clinical usefulness are limited, since the CT score is largely affected by coexisting lung disease. Hence, we hypothesized that numerical change in CT score during the observation period may be useful for evaluating disease activity of Mab-PD.
Methods
Patients diagnosed with Mab-PD based on the official ATS/ERS/ESCMID/IDSA statement at Jikei University Hospital and Jikei Daisan Hospital between 2015 January 1 and 2021 July 31 were included (n = 32). We reviewed the medical records, and bacteriological and laboratory data of the patients. Chest CT was performed at diagnosis in all 32 cases. In 18 cases, chest CT images within 4 years before diagnosis were available. The numerical change in CT score between two time points was calculated and the association of the CT scores with sputum Gaffky score and serum CRP was examined.
Citation: Shinfuku K, Hara H, Takasaka N, Ishikawa T, Araya J, Kuwano K (2023) The usefulness of change in CT score for evaluating the activity of Mycobacterium abscessus (Mab) pulmonary disease (Mab-PD). PLoS ONE 18(2): e0281103. https://doi.org/10.1371/journal.pone.0281103
Editor: Frederick Quinn, The University of Georgia, UNITED STATES
Received: October 30, 2022; Accepted: January 13, 2023; Published: February 8, 2023
Copyright: © 2023 Shinfuku et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data cannot be shared publicly because of privacy of the patients. Data from this study are available upon request (Hiromichi Hara, E-mail: hirohara@jikei.ac.jp or ethics committee of Jikei University, E-mail: crb@jikei.ac.jp).
Funding: he author(s) received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Abbreviation list: Mab, Mycobacterium abscessus; MAC, M.avium complex; NTM, non-tuberculous mycobacteria; PD, Pulmonary disease
Introduction
In recent years, the incidence of non-tuberculous mycobacterial (NTM) infections increases worldwide, including in Japan [1, 2]. Among them, Mycobacterium abscessus (Mab) infections are rapidly increasing. Mab is one of the rapidly growing NTM groups [3, 4]. It belongs to s group IV in Runyon classification, composed of three subspecies (M. abscessus subsp. abscessus, M. abscessus subsp. massiliense and M. abscessus subsp. bolletii.) [3]. Mab is ubiquitous in the environment including soil and tap water, which causes chronic infection in skin, bone, and respiratory organs in humans [5]. Mab Pulmonary disease (Mab-PD) is generally treated with combinations of several intravenous and oral agents based on its disease activity [3, 6, 7].
Although an Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline for NTM pulmonary disease was published in 2020 [3], a variety of clinical issues including evaluation of disease activity, selection of medical agents, timing of treatment, and duration of treatment remain unresolved. Evaluation of disease activity of Mab-PD is the initial and important step for deciding the administration of treatment. The activity of Mab-PD is commonly evaluated by the patient’s symptoms, serum CRP, amount of mycobacteria in sputum, and CT findings. However, symptoms are not quantitative; CRP is less sensitive. amount of mycobacteria in sputum is highly variable, in addition, sputum samples cannot be obtained timely. Hence, semi-quantitative CT score evaluating severity and extent of bronchitis, bronchiectasis, cavity, nodule, and consolidation is generally used for assessing disease activity and severity for Mab-PD [8]. However, its clinical usefulness is limited, since these CT findings are not specific for Mab-PD, and the score can be affected by coexisting lung disease [9–11]. Accordingly, in comparison to a single evaluation of CT score at the timing of diagnosis, we hypothesized that numerical change in CT score during the observation period may be useful for precisely evaluating disease activity of Mab-PD. In this study, we examined the clinical usefulness of CT score at diagnosis and its chronological change from prior to diagnosis to the timing of diagnosis of Mab-PD.
Methods
Study subjects
This study is a retrospective cohort study of patients diagnosed with Mab-PD based on the official ATS/ERS/ESCMID/IDSA statement [3] at Jikei University Hospital and Jikei Daisan Hospital from January 1, 2015 (01/01/2015) to July 31, 2021 (07/31/2021). Patients were eligible for the study if they met the following inclusion criteria 1) Age ≥ 20 years old, 2) patients diagnosed with Mab-PD based on the official ATS/ERS/ESCMID/IDSA statement.
A total of 32 patients were included in this study. Among them, 13 patients were included in our previous report [12]. This study was approved by the Ethics Committee of Jikei University (33–219 (10836)), and adhered to the tenet of medical ethics. We performed opt-out consent on the website of our hospital, based on the ethical guidelines of Jikei University. (Informed consent was not necessary for this retrospective study). Patients’ medical records from 2015 (01/01/2015) to July 31, 2021 (07/31/2021) were accessed. All data were fully anonymized after collecting from the medical records and used for further statistical analysis. Chest CT images were evaluated by two specialists of the Japanese Respiratory Society (H.H. and K.S.). Data from this study are available upon request (Hiromichi Hara, E-mail: hirohara@jikei.ac.jp or ethics committee of Jikei University, E-mail: crb@jikei.ac.jp).
Diagnosis of Mab-PD
Respiratory samples from patients with clinical suspicion of NTM pulmonary disease were cultured on Ogawa media or Mycobacteria Growth Indicator Tube, and species of cultured mycobacteria were determined by mass spectrometry or DDH (SRL, Inc. laboratory, Tokyo, Japan). According to the official ATS/ERS/ESCMID/IDSA statement, a diagnosis of Mab-PD was made [3].
Data collection
We retrospectively reviewed the medical records of the enrolled patients. Clinical characteristics including age, sex, BMI, smoking history, comorbidities, coexisting lung disease, and Gaffky score in sputum were investigated. The maximum number of Gaffky scores (Gaffky score; a scale assessing the number of mycobacteria bacilli present, 0–10) at diagnosis was selected [13]. CT score was calculated using a scoring system for Mab-PD [8] by HH or KS. A total score of 30 was allocated for five types of lung lesions including bronchiectasis (Severity;3 points, Extent;3 points, Mucus plugging; 3 points, total 9 points), bronchiolitis (Severity;3 points, Extent;3 points, total 6 points), cavity (Diameter; 3 points, Wall thickness; 3 points, Extent;3 points, total 9 points), nodule (3 points), and consolidation (3 points) depending on the severity of lung lesions [8]. The difference of absolute value and change rate in CT score (based on the difference of CT scores between at diagnosis and immediate past CT score) were calculated.
Statistical analysis
Simple linear regression analysis was performed to estimate the association of CT score at diagnosis of Mab-PD with sputum Gaffky score, and serum CRP. The association of changes in two time points CT scores with sputum Gaffky score, serum CRP was also examined. All statistical analyses were performed using GraphPad Prism version 8.4.3 for Macintosh (GraphPad Software La Jolla, CA, USA), and the statistical significance was set at P < 0.05.
Results
Clinical background of Mab-PD (Table 1)
The Clinical backgrounds of all Mab-PD patients were shown (n = 32, Table 1). Twenty-eight patients (88%) had coexisting pulmonary diseases such as bronchiectasis, prior pulmonary tuberculosis, obstructive pulmonary disease (chronic obstructive pulmonary disease, Asthma, bronchiolitis obliterans) and interstitial lung disease. Serology showed no or slight elevation of white blood cell counts and CRP levels.
CT score at diagnosis of Mab-PD lung lesions (Table 2)
The severity and extent of ‘bronchiectasis’ and ‘cellular bronchiolitis’ were higher than the other parameters. ‘Bronchiectasis’ and ‘cellular bronchiolitis’ were characteristic findings of Mab-PD. The mean total score was 9.8 (Max 30).
Correlation of CT score at the timing of diagnosis with sputum Gaffky score and serum CRP
Correlation of CT score at the timing of diagnosis with sputum Gaffky score (Fig 1A) and CRP (Fig 1B) are shown. No significant correlations were demonstrated in either case.
Correlation between CT score at the timing of diagnosis with sputum Gaffky score (Fig 1A) and CRP (Fig 1B) are shown.
Correlation of chronological change in CT score with sputum Gaffky score and serum CRP
In 18 patients of 32 patients, chest CT was performed for follow-up of other diseases within 4 years before the diagnosis of Mab-PD (Table 2). The numerical changes in CT score between at diagnosis and immediate past CT score was calculated. The difference in CT score between two time points was well correlated with sputum Gaffky score (Fig 2A) and CRP (Fig 2B), respectively. The largest difference was observed in the category of severity in ‘cellular bronchiolitis’ (previous CT:1.0, CT at diagnosis: 1.7). Next, the change rate in CT score was calculated by dividing by month, which was also correlated with sputum Gaffky score (Fig 2C) and CRP (Fig 2D), respectively.
Correlation between the difference of CT scores with sputum Gaffky score (Fig 2A) and CRP (Fig 2B) are shown. The change rate in CT score was also correlated with sputum Gaffky score (Fig 2C) and CRP (Fig 2D), respectively.
Discussion
In this study, we demonstrated that CT score at diagnosis was not correlated with sputum Gaffky score and serum CRP, but the difference of absolute value and change rate in CT score between at diagnosis and immediate past CT was well correlated with both sputum Gaffky score and serum CRP. Accordingly, chronological change in CT score may more precisely reflect the disease activity of airway mycobacterial burden and systemic inflammation in Mab-PD.
Mab colonizes airway or lung tissue, especially in the setting of disease complicated lungs after inhalation of the pathogen. Decreased local or systemic host defense may affect the subsequent distribution of the mycobacteria into lung tissues, resulting in Mab-PD development. When Mab is detected in the respiratory specimens, it is critically important to determine whether simple colonization or Mab-PD development for treatment administration at the appropriate timing. Although a semi-quantitative CT score is generally used for assessing Mab-PD activity [9], its clinical usefulness is limited, since the score is affected by high frequent coexisting lung disease. Indeed, in the present study, CT score at diagnosis did not correlate with sputum Gaffky score or serum CRP. However, the difference and change rate of CT score between at diagnosis and immediate past CT score (chronological change in CT score), significantly correlated with both the sputum Gaffky score and CRP. It has been recognized that sputum Gaffky score reflects bacteriological activity and CRP reflects the serological activity. It is plausible that chronological change in CT score can be an important indicator reflecting both bacteriological and serological activity of Mab-PD. Accordingly, it is important to evaluate the CT score at multiple time points at the timing of diagnosis and chronological change should be used as an indicator of radiological activity if previous CT scans were available. Chronological change of CT scores might be useful in assessing disease activity in other NTM-PDs, which should be elucidated in future studies. Progression of PD might at least partly depend on growth speed of the mycobacteria, hence, we speculate that change of CT scores of rapidly growing mycobacteria including Mab might be more detectable than slowly growing mycobacteria including MAC.
Among the parameters of CT evaluation, the largest difference in severity was observed in the category of ‘cellular bronchiolitis’. Since ‘cellular bronchiolitis’ is not necessarily accompanied by tissue destruction, CT findings might be promptly changeable reflecting disease activity, compared to other parameters with severe tissue destruction including ‘bronchiectasis’ and ‘cavitation’.
There are several limitations of this study. First, this retrospective study included a small number of cases, which can be attributed to the relatively small number of Mab-PD cases compared to MAC-PD cases in Japan. And, the results in this study could be affected by an outlier effect. Data from a single patient were separated from the rest of the patients. We reviewed in detail the medical record of the patient, and concluded that delayed diagnosis led to advanced pulmonary involvement and elevated sputum bacterial counts and serum CRP. However, no obvious reason was found to exclude the patient from this study. When outlier tests were performed by Inter Quartile Range (IQR) method(Tail Quantile 0.1 Q3) and Robust estimation method (Huber M-estimation K sigma 4) using JMP Pro16 Software (SAS Inst. Inc., Cary, NC), no outliers were found. Hence, we included this patient in the study. (Even after excluding that patient, the change in CT scores was still significantly correlated with the sputum Gaffky score. However, there was no significant difference in the association between the change in CT scores and CRP if the patient was excluded. CRP might be less likely to rise in patients with mild lesions, and was less likely to reflect disease activity than sputum Gaffky score.) Second, previous CT scans were not available in around half of the cases in this study and CT score at the timing of diagnosis did not reflect the disease activity of Mab-PD. Third, due to the retrospective nature of this study, the interval between CT scans was variable in each case, which may have an impact on not only the difference in CT score but also on the usefulness for predicting disease activity. Although our results suggest that difference in CT score in the setting of less than a 4-year interval may reflect disease activity, we speculate that the change rate in CT score under short-term observation will be a more accurate indicator of Mab-PD activity, which should be examined in a future validation cohort study. Progression of other lung diseases than Mab-PD might affect chronological change of CT scores, which was not clinically evident during this observation period.
Conclusions
Chronological change in CT score may more precisely reflect disease severity of airway mycobacterial burden and systemic inflammation in Mab-PD at the timing of diagnosis.
Supporting information
S1 Fig. Samples of CT scoring (Bronchiectasis, bronchiolitis, cavity).
https://doi.org/10.1371/journal.pone.0281103.s001
(TIF)
References
- 1. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015; 36: 13–34.
- 2. Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis 2016; 22: 1116–7.
- 3. Daley CL, Iaccarino JM, Lange C, Camhau E, Wallace RJ jr, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 2020; 56: 2000535.
- 4. Victoria L, Gupta A, Gómez JL, Robledo J. Mycobacterium abscessus complex: A Review of Recent Developments in an Emerging Pathogen. Front Cell Infect Microbiol 2021; 11: 659997.
- 5. Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol 2020; 18: 392–407.
- 6. Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180: 896–902.
- 7. Hawoth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017; 72 (Suppl 2): ii1‒64. pmid:29054853
- 8. Kim HS, Lee KS, Koh WJ, Jeon K, Lee EJ, Kang H, et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology 2012; 263: 260–70.
- 9. Tung YJ, Bittaye SO, Tsai JR, Lin CY, Huang CH, Chen TC, et al. Risk factors for microbiologic failure among Taiwanese adults with Mycobacterium abscessus complex pulmonary disease. J Microbiol Immunol Infect 2015; 48: 437–445.
- 10. Uno S, Asakura T, Morimoto K, Yoshimura K, Uwamino Y, Nishimura T, et al. Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis. BMC Pulm Med 2020; 20: 262. pmid:33036598
- 11. Szturmowicz M, Oniszh K, Wyrostkiewicz D, Radwan-Rohrenschef P, Filipczak D, Zabost A. Non-Tuberculous Mycobacteria in Respiratory Specimens of Patients with Obstructive Lung Diseases-Colonization or Disease? Antibiotics (Basel) 2020; 9: 424. pmid:32698511
- 12. Hara H, Okuda K, Araya J, Utsumi H, Takekoshi D, Ito S, et al. Possible relationship between esophagal dilation and severity of M.abscessus pulmonary disease. PLOS ONE 2021; 16: 0261866.
- 13.
Technical guidance for Mycobacterial examination 2020. The Japanese society for tuberculosis and non-tuberculous mycobacteriosis, 2020: nankodo p36.